Drug prescription is difficult to manage in patients with chronic kidney disease (CKD). We assessed the prevalence and determinants of inappropriate drug prescriptions (whether contraindications or inappropriately high doses) with regard to kidney function in patients with CKD under nephrology care. We also assessed the impact of the equation used to estimate GFR on the prevalence estimates.
Introduction
Chronic kidney disease (CKD) is associated with multiple comorbidities and a particularly high level of polymedication [1] . Medication is often difficult to manage, since the decline in the glomerular filtration rate (GFR) greatly alters the pharmacokinetics and pharmacodynamics of kidney excreted drugs [2, 3] . Indeed, the dosage of many drugs may need to be reduced in patients with poor kidney function, in order to avoid drug accumulation, toxicity and the accelerated progression of CKD [4] . Optimal drug management should be an important target for preserving kidney function. Indeed, a recent Clinical Practice Guideline for the evaluation and management of CKD (issued by the Kidney Disease Improving Global Outcomes, KDIGO) [5] contains the following Grade 1A (the highest) recommendation: 'We recommend that prescribers should take GFR into account when drug dosing'. However, putting this recommendation into practice is challenging in view of (i) differences between the available guidelines on dose adjustment, and (ii) the lack of standardized guidelines on estimating kidney function for drug dosing.
Most studies of drug prescriptions and dose adjustments with regard to kidney function have been performed in elderly patients. In the literature, the proportion of patients with inappropriate prescriptions with regard to kidney function varied from 13 to 53% [6] [7] [8] [9] ; these disparities may be due to heterogeneity in the study design (retrospective design based on reimbursement claims vs. prospective studies, for example), the study population and/or the equation used to estimate kidney function. Data regarding drug prescriptions and their adjustment to kidney function are scarce in patients consulting in a nephrology department and have been infrequently evaluated in prospective cohort studies. Furthermore, few studies reported on both medication dosing and the level of kidney function. The few published reports in CKD patients were only designed to evaluate specific drug classes [10, 11] .
When adapting drug doses, selection of the most appropriate tool for assessing the GFR is a challenge. The Cockcroft-Gault (CG) equation is most frequently applied during the development of many drugs. However, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is now implemented worldwide for classifying and monitoring CKD patients; it is indexed to body surface area and so it might be necessary to de-index this equation in CKD patients requiring dose adaptation [12, 13] .
Hence, the main objective of the present study was to investigate the prevalence and determinants of inappropriate drug prescriptions (whether contraindications or inappropriately high doses) with regard to kidney function in patients with CKD under nephrology care. We also assessed the impact of the equation used to estimate eGFR on the prevalence estimates.
Methods

Study design and participants
CKD-REIN (Chronic Kidney Disease -Renal Epidemiology and Information Network) is a representative, prospective cohort study carried out in 40 nephrology outpatient facilities in France. Enrolled patients were at least 18 years of age, under nephrology care with a confirmed diagnosis of CKD stages 3-5 (estimated GFR (eGFR) <60 ml min À1 1.73 m À2 , no previous chronic dialysis or kidney transplantation). A total of 3033 patients were included. Details of the study protocol have been published elsewhere [14, 15] . The study protocol was approved by the institutional review board at the French National Institute of Health and medical research (INSERM; reference: IRB00003888). The study was registered at ClinicalTrials.gov (NCT03381950).
Data collection and routine laboratory measurements
Patient-level forms were completed by trained clinical research associates (CRAs) on the basis of a patient interview and the inspection of medical records. Detailed definitions of comorbidities have been published elsewhere [15] . Selfadministered patient questionnaires were used to assess medication adherence on the Girerd score [16] and frequency of consultation to family physicians and specialist physicians.
Patients were asked to bring all their drug prescriptions (regardless of the prescribing physician) for the three months immediately preceding the interview with a CRA. The CRAs used an electronic case report form (linked to the international Anatomical Therapeutic and Chemical (ATC) [17] thesaurus) to enter standardized ATC codes. This specifically designed system enabled (i) coding by non-medical staff, (ii) documentation of a defined daily dose (DDD), and (iii) easier data mining. For each drug prescription, the trade name, international non-proprietary name, ATC class, unit dose, DDD, pharmaceutical formulation, and administration route can be easily extracted from our database.
The patient's height and weight were measured during the enrolment visit. Body surface area (BSA) was calculated using the Dubois equation [18] . Routine serum creatinine values were collected from hospital and local laboratories and GFR was estimated with the CKD-EPI creatinine equation [19] . Kidney function was also estimated using the Cockcroft-Gault (CG) equation [20] for creatinine clearance (CrCl). We calculated a GFR de-indexed from BSA.
Definition of inappropriate drug prescriptions with regard to the kidney function
We analysed the appropriateness of all drug prescriptions in the three months immediately preceding study enrolment. First, two pharmacists (S.M.L. and S.L.) studied a variety of documents in order to choose the most exhaustive source of dosing recommendations or contraindications with regard to kidney function. Few of the 779 substance codes (prescribed to included patients) had precise international recommendations on dose adaptation. Summaries of product characteristics (SPCs, approved by the regulatory authorities and updated annually) constituted the most detailed source of recommendations [21] . The SPC corresponds to the Physician's Desk Reference and should be used as the reference for prescribing as it constitutes formal evidence in legal proceedings. Each drug's SPC was reviewed to extract any dosing guidelines or contraindications with regard to kidney function (Table S1A) . For each substance, we defined a threshold above which the drug was contraindicated or required dose adjustment in proportion to the patient's kidney function. As a sensitivity analysis, we examined antidiabetic agents, for which detailed international and European guidelines have been published in KDOQI 2012 [22] (Table S1B) and European Renal Best Practice [23] (Table S1C) . We combined these two sets of guidelines with the SPCs, in order to define CKD-related dose adaptations for these drug classes.
Inappropriate prescription was defined as the reported prescription of either a contraindicated drug or an indicated drug prescribed at an inappropriately high dose level with regard to the patient's GFR. In the main analysis, we used the CKD-EPI creatinine equation to estimate the GFR. We performed sensitivity analysis to evaluate the proportion of inappropriate prescriptions for the CG equation and the deindexed CKD-EPI creatinine equation.
Statistical analyses
Baseline characteristics were described for patients with at least one drug prescription as a whole and for CKD stage sub-groups (defined according to the CKD-EPI creatinine equation), and were expressed as the mean ± standard deviation (SD), the median [interquartile range (IQR)] or the number (percentage). In 3011 patients with at least one prescription, proportions of patients with at least one inappropriate prescription were assessed overall and by drug class, according to the GFR estimated by the CKD-EPI creatinine equation.
The numbers of contraindicated and inappropriately high dose drug prescriptions, and the proportions of patients with at least one inappropriate prescription, were compared for the three equations used to estimate kidney function (CKD-EPI, CG, and de-indexed CKD-EPI) in 2941 patients with data on their weight and height. Next, we studied the level of agreement in evaluating appropriateness between the different equations by calculating Cohen's kappa. A value of <0.6 was defined as poor agreement, 0.6 to <0.8 was defined as moderate agreement, 0.8 to <0.9 was defined as good agreement and ≥0.9 was defined as excellent agreement.
Lastly, multivariate logistic regression was used to assess the determinants of inappropriate prescription risk, i.e. exposure to at least one inappropriate prescription (expressed as the odds ratio (OR) [95% confidence interval (CI)]). Selection of the variables included in the multivariate models was based on a literature review and a p-value below 0.2 in a univariate analysis. In view of missing data for some variables, we performed multiple imputations of 10 datasets with the fully conditional specification method [24] . The imputation model included all the variables in Table 3 and baseline eGFR and serum creatinine values. Logistic regression was performed on each complete dataset and the estimated ORs were combined according to Rubin's rules. Statistical analyses were performed using SAS software (version 9.4, SAS Institute Inc., Cary, NC) and R software (version 3.3.1, Foundation for Statistical Computing, Vienna, Austria).
Results
Characteristics of the population at baseline
Among the 3033 patients in the CKD-REIN cohort, 3011 had at least one drug prescription. The participants' characteristics are summarized in Table 1 had a BMI greater than 30 kg m À2 . Most of patients had a history of hypertension, and 43% were diabetic. More than 65% of the patients reported visiting their nephrologist once to twice a year. Almost 60% of the patients said that they had visited their family physician more than four times during the year preceding inclusion in the cohort ( Table 1 ). The number of visits to family physicians and nephrologists increased with the CKD stage ( Table 1) .
Characteristics of drug prescriptions
The median [IQR] number of prescribed medications per patient was 8 [5; 10] , and 2182 (72%) patients had been prescribed six or more drugs. The median number of prescribed drugs per patient was positively correlated with the severity of CKD, rising from 6 [4; 9] in stages 2 and 3A to 8 [6; 11] in stages 4 and 5 (Table 1) . Among the 3011 patients with at least one drug prescription, the four most frequently prescribed classes were cardiovascular agents, antidiabetic agents, drugs for acid-related gastrointestinal disorders and anti-gout preparations (Tables 2 and S2 ). Data are quoted as the mean ± SD, the median [interquartile range] or %.
Prevalence of contraindicated and inappropriately high dose drug prescriptions
When using the CKD-EPI equation to evaluate kidney function, 31% of the patients had been prescribed at least one contraindicated drug, and 35% had been prescribed at least one drug at an inappropriately high dose level with regard to their eGFR. The proportion of inappropriate prescriptions was greater in patients at CKD stages 4 and 5. Indeed, when considering patients with an eGFR below 30 ml min À1 1.73 m À2 , 57% had been prescribed at least one contraindicated drug, and 42% had received a prescription for an inappropriately high dose level ( Figure 1 ). Overall, 52% of treated patients presented at least one inappropriate prescription, and 22% had received two or more inappropriate prescriptions ( Figure S1A ). Sixty-five per cent of the patients had not been prescribed any drugs at an inappropriately high dose level ( Figure S1B ). Seventy per cent of the patients had not been prescribed any contraindicated drugs ( Figure S1C) .
The proportions of patients with inappropriate prescriptions among drug classes, by eGFR, are summarized in Table 2 . Among drug classes prescribed in more than one third of patients, the highest proportion of inappropriate prescriptions were observed for anti-gout, cardiovascular system and antidiabetic drugs, with respectively 41%, 27% and 21% of patients treated with these drugs having at least one inappropriate prescription.
Three drugs (allopurinol, ramipril and perindopril) accounted for more than half of the inappropriately high dose prescriptions (n = 701/1299) (Table S3) . Nevertheless, when removing allopurinol, ramipril and perindopril prescriptions, for which benefit may have been considered higher than risk by prescribers, the proportion of patients with inappropriate prescription remained high (41%). For the 777 patients receiving the urate-lowering agent allopurinol, 51% of the prescriptions were at an inappropriately high dose level. Forty-one per cent of the colchicine prescriptions concerned patients with an eGFR below 30 ml min À1 1.73 m
À2
(n = 26/64). The number of prescriptions of non-steroidal anti-inflammatory drugs in patients with an eGFR below 30 ml min À1 1.73 m À2 was relatively low (n = 9), as was the number of prescriptions of salicylic acid derivatives (used as an analgesic and/or antipyretic, i.e. >160 mg day À1 ) (n = 29). In addition, 40% of the prescriptions for oral antidiabetic agents were inappropriate (n = 253/641). The most frequently employed drug was metformin; 17% of metformin prescriptions corresponded to contraindications, and 33% corresponded to inappropriately high doses with regard to the patient's eGFR. It is noteworthy that the proportion of patients with inappropriate prescription of antidiabetic agents was similar when the SPC, KDOQI or European Renal Best Practice recommendations were applied ( Figure S2 ).
Prevalence of inappropriate prescription according the CG, CKD-EPI and de-indexed CKD-EPI equations
The proportions of patients with at least one contraindicated prescription or at least one inappropriately high dose prescription differed significantly according to the equation used to estimate kidney function (P < 0.0001). The CKD-EPI equation yielded higher proportions (52%) than the CG equation (41%) and the de-indexed CKD-EPI equation (47%) (Figure 2 and Figure S3 ). Of the 1285 prescriptions considered to be contraindicated when the kidney function was calculated with the CKD-EPI equation, 557 were not considered to be contraindicated with regard to the CG equation (kappa CG vs. CKD-EPI = 0.69) ( Table S4A ). The level of agreement between the CG equation and the de-indexed CKD-EPI equation was higher (kappa CG vs. De-indexed CKD-EPI = 0.81).
When considering the 1275 inappropriately high dose prescriptions when the kidney function was calculated with the CKD-EPI equation, 337 were not considered to be inappropriately high dose prescriptions with regard to the CG equation (kappa = 0.82) (Table S4B ).
Figure 1
Percentage of patients with at least one contraindicated prescription, at least one inappropriately high dose prescription, or at least one inappropriate prescription (i.e. a contraindicated or inappropriately high dose drug), by CKD stage (assessed using the CKD-EPI equation) (continues)
Determinants of inappropriate drug prescription
As expected, the OR for the risk of an inappropriate prescription rose with the CKD stage (P for trend < 0.0001) ( For each drug class and each CKD group, we reported the number of treated patients and calculated the proportion of patients with at least one contraindicated drug, at least one inappropriately high dose drug, and at least one inappropriate prescription (i.e. contraindicated or inappropriately high dose drug).
Discussion
The present study is the first to focus on drug prescriptions and their adjustment to the kidney function in a large and representative cohort of CKD patients monitored by nephrologist. We confirmed that polymedication is common among non-dialysed patients with CKD: 72% of the study participants had been prescribed more than five drugs. A high proportion of study participants (52%) had received one or more inappropriate prescriptions (i.e. a contraindicated or inappropriately high dose drug) with regard to the eGFR. The number of prescribed drugs appeared to be the main determinant of inappropriate prescription. Our data highlight the complexity of prescription in the CKD setting, due in part to the lack of up-to-date guidelines on dose level adjustments in patients with impaired kidney function. Lastly, we observed that the choice of the CKD equation led to marked differences in the proportion of inappropriate prescriptions, with the CG equation yielding the lowest prevalence of inappropriate prescriptions. A high prevalence of inappropriate prescriptions has already been documented in elderly patients with altered kidney function. In a French cohort of elderly patients [6] , 53% of the individuals with an eGFR between 30 and 59 ml min À1 1.73 m À2 were exposed to a risk of inappropriate drug use. However, 14% of the patients in the latter study had an eGFR below 60 ml min À1 1.73 m À2 , and only 25 patients had an eGFR below 30 ml min À1 1.73 m À2 . Furthermore, drug dose levels were not recorded, and so only the potential risk of inappropriate or inappropriately high dose drug use could be estimated. In the USA, a retrospective study of older veterans [9] showed that 13% of the individuals with a CrCl rate between 30 and 49 ml min À1 and 29% of the individuals with a CrCl rate between 15 and 29 ml min À1 were prescribed at least one drug that was contraindicated or used at an inappropriately high dose with regard to their kidney function. In an Australian study of patients aged 65 and over [8] , 28% of the participants received inappropriate medications with regard to their kidney function. These two reports were retrospective (i.e. based on reimbursement database) and focused on a prespecified list of drugs. The majority of published data on inappropriate prescriptions concerns elderly patients with impaired renal function. We extended these investigations to patients with a confirmed diagnosis of CKD and an accurate, prospective record of drug dose levels. In the CKD-REIN cohort, 31% of the patients had been prescribed at least one contraindicated drug and 35% had been prescribed at least one inappropriately high dose drug with regard to their eGFR. The high proportion of patients receiving inappropriate prescriptions (with regard to SPCs) suggests that clinicians do not always adopt the guidelines issued by health authorities. In fact, CKD patients are often excluded from participating in large clinical trials. Information on the adjustment of drug dosing, particularly the contraindicated part, is often imprecise or even inaccessible, and is rarely validated by clinical trial results. Indeed, old drugs that have not been tested in patients with CKD are systematically contraindicated in this population. Hence, if a physician believes that a guideline is not valid, he/she will be less likely to adopt and implement it; the prescription of contraindicated drugs will be not uncommon if he/she thinks that the risk/benefit ratio is still favourable for the patient or if there are no alternative treatments. In contrast to recommendations on contraindications, recommendations on dose adaptations seem to be less controversial because they are justified by the risk of accumulation of drugs excreted by the kidneys. However, our results suggest that prescribers are not aware of or do not apply many of these adjustment guidelines.
Hyperuricaemia is a frequent complication in CKD patients; in the present study, 34% of the participants received at least one uricosuric agent (most frequently Figure 2 Percentage of patients with at least one contraindicated prescription, at least one inappropriately high dose prescription or at least one inappropriate prescription (i.e. a contraindicated or inappropriately high dose drug) by CKD stage according to the CKD-EPI equation, the de-indexed CKD-EPI equation and the Cockcroft-Gault equation. The analyses were restricted to the 2941 patients with data on weight and height Table 3 Factors associated with having at least one inappropriate prescription when renal function was estimated with the CKD-EPI equation Adequacy of drug prescriptions in CKD patients allopurinol). The dose of allopurinol must be adjusted as a function of the eGFR because the elimination half-life of oxypurinol (the active metabolite) is significantly longer in patients with kidney failure. Furthermore, the frequency of allopurinol-associated adverse events is higher in this type of patient [25, 26] . In the present study, half of all the allopurinol prescriptions (i.e. in 395 patients) were classified as an inappropriately high dose of this hypouricemic agent. It is noteworthy that other researchers have also reported on inappropriate prescriptions of allopurinol [9, [27] [28] [29] . Although the latter studies (predominantly in elderly patients) were performed with other designs and other reference guidelines, the results nevertheless suggest that prescribing physicians are not aware of the need to adjust the allopurinol dose level as a function of the eGFR. Diabetes is one of the leading causes of CKD worldwide [1] . In the present study, more than a third of patients were being treated for diabetes. A large proportion of antidiabetic agents are excreted by kidney, and the accumulation of these drugs can lead to adverse events. These particularities have prompted international learned societies to issue guidelines on dose adjustments [22, 23] . In the present study, application of the SPCs, the European guidelines and the international guidelines gave approximately the same proportion of patients with at least one inappropriate prescription of an antidiabetic agent. This observation suggests that our present findings are not restricted to France and may have international implications. Indeed, the proportion of inappropriate prescriptions in the CKD-REIN cohort was high -as seen in studies of elderly adults that referred to other guidelines (e.g. LexiComp ® , pharmaceutical compendia and other drug guideline databases). Unsurprisingly, a high number of prescribed drugs was the main determinant of inappropriate prescriptions in the present study. The oldest patients were less likely to have inappropriate prescriptions, suggesting that physicians take more account of kidney function when prescribing drugs to elderly patients. In contrast to a literature report [9] , the number of consultations with a nephrologist did not appear to protect against inappropriate prescriptions. However, all the patients were being followed up in a nephrology department in the CKD-REIN study, leading to difficulty in comparing the two studies. They were more likely to consult a family physician: 57% of the patients reported having seen their family physician more than 4 times a year, whereas only 35% reported seeing a nephrologist more than 3 times a year. These findings suggest that the family physician represents an important prescriber in this population, hence the need to reinforce the dissemination of information and guidelines on drug management in patients with CKD -particularly for family physicians.
The prevalence of inappropriate prescriptions depends strongly on the equation used to estimate kidney function. Indeed, we found that according the equation used, the proportion of inappropriate, inappropriately high dose and contraindicated drugs varied significantly. Upon inclusion in the present study, the mean ± SD eGFR was 33 ± 12 ml min À1 1.73 m À2 (according to the CKD-EPI equation) and the mean ± SD CrCl rate was 41 ± 16 ml min
À1
(according to the CG equation). This discrepancy might be due to a relatively high BMI in the present cohort, which may have greatly influenced the proportion of inappropriate prescriptions. The proportion of patients with at least one contraindicated drug was 20% when kidney function was evaluated with the CG equation and 30% when kidney function was evaluated with the CKD-EPI equation. Most of the guidelines on adjusting drug dose levels to kidney function have used the CG equation [30, 31] . However, nephrologists also classify and monitor CKD patients with reference to the CKD-EPI equation, which is acknowledged to produce the best estimation of actual kidney function [5, 19] . It would have been useful for us to know whether physicians use the two equations in distinct ways or whether they use the CKD-EPI equation to calculate the eGFR and then adjust the drug dose accordingly. A main concern here is the indexation of the CKD-EPI equation with regard to the BSA (1.73 m À2 for an average-sized person). Thirty-six per cent of the patients in the CKD-REIN cohort had a BMI of more than 30 kg m À2 , and thus had a BSA of more than 1.73 m À2 . Hence, the use of the de-indexed CKD-EPI equation to adjust drug dose levels appears to be a good compromise. This might be especially true for CKD patients with a high BMI; we found that the proportion of inappropriate prescriptions changed when the patient's kidney function was evaluated with the de-indexed CKD-EPI equation. The present study had several major strengths. It constitutes the ever first study of inappropriate drug prescriptions in a large (n > 3000) cohort of nephrology department outpatients with a confirmed diagnosis of CKD. Indeed, previous studies of inappropriate drug prescriptions focused on elderly adults [6] [7] [8] [9] . Our prospective data collection and especially a detailed survey of prescribed drugs and dose levels also constitute a major strength.
The study also had some limitations. Only prescription medications were analysed here; in fact, some overthe-counter drugs are also not recommended in patients with impaired kidney function. We performed the analyses using only three of the many equations available; other available equations include the Berlin Initiative Study equation [32] , the results of which could have been slightly different. Lastly, we analysed prescriptions in the three months preceding study inclusion; this might have underestimated the proportion of inappropriate prescriptions in some drug classes (e.g. antibiotics). Moreover, data on chronic treatments (i.e. long-term prescriptions) can be collected with more reliability than data on short-term prescriptions. Linking the CKD-REIN database to a reimbursement dataset should provide us with better insight in these cases [33] .
Conclusion
The CKD-REIN study provided us with a good opportunity to evaluate inappropriate drug prescriptions in a large, representative, French cohort of CKD patients being followed up in a nephrology clinic. Of the 3011 patients receiving medication, 52% had at least one inappropriate prescription (i.e. a prescription of a contraindicated drug or a drug that was prescribed at an inappropriately high dose level with regard to the patient's kidney function). This high proportion emphasizes the complexity of drug prescribing in CKD, given the many different prescription guidelines and the various equations used to estimate kidney function. It remains to be determined whether these inappropriate prescriptions impact clinical outcomes (i.e. iatrogenic events, hospitalizations and mortality).
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